Compare Stocks: ABCM, UTHR, GMAB, and BBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCM Abcam	$23.99	$23.88	$12.48 ▼ $25.32	$5.50B	0.86	3.08 million shs	N/A
BBIO BridgeBio Pharma	$79.89 +0.0%	$77.61	$46.81 ▼ $93.42	$15.61B	0.96	2.09 million shs	2.80 million shs
GMAB Genmab A/S	$32.84 +2.8%	$28.14	$23.22 ▼ $35.43	$19.92B	0.83	2.21 million shs	3.43 million shs
UTHR United Therapeutics	$508.48 +1.8%	$535.22	$302.19 ▼ $609.35	$21.43B	0.59	521,068 shs	457,341 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCM Abcam	0.00%	0.00%	0.00%	0.00%	0.00%
BBIO BridgeBio Pharma	0.00%	-5.47%	-1.87%	+22.26%	+55.61%
GMAB Genmab A/S	0.00%	+2.21%	+11.21%	+21.12%	+37.02%
UTHR United Therapeutics	0.00%	-7.26%	-6.71%	-11.86%	+59.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCM Abcam	$23.99	$23.88	$12.48 ▼ $25.32	$5.50B	0.86	3.08 million shs	N/A
BBIO BridgeBio Pharma	$79.89 +0.0%	$77.61	$46.81 ▼ $93.42	$15.61B	0.96	2.09 million shs	2.80 million shs
GMAB Genmab A/S	$32.84 +2.8%	$28.14	$23.22 ▼ $35.43	$19.92B	0.83	2.21 million shs	3.43 million shs
UTHR United Therapeutics	$508.48 +1.8%	$535.22	$302.19 ▼ $609.35	$21.43B	0.59	521,068 shs	457,341 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCM Abcam	0.00%	0.00%	0.00%	0.00%	0.00%
BBIO BridgeBio Pharma	0.00%	-5.47%	-1.87%	+22.26%	+55.61%
GMAB Genmab A/S	0.00%	+2.21%	+11.21%	+21.12%	+37.02%
UTHR United Therapeutics	0.00%	-7.26%	-6.71%	-11.86%	+59.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCM Abcam	0.00	N/A	N/A	N/A
BBIO BridgeBio Pharma	2.83	Moderate Buy	$100.79	26.16% Upside
GMAB Genmab A/S	2.85	Moderate Buy	$39.50	20.28% Upside
UTHR United Therapeutics	2.85	Moderate Buy	$646.00	27.05% Upside

Current Analyst Ratings Breakdown

Latest ABCM, UTHR, GMAB, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	UTHR United Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/12/2026	BBIO BridgeBio Pharma	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$102.00 ➝ $107.00
8/12/2026	BBIO BridgeBio Pharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$104.00 ➝ $106.00
8/12/2026	BBIO BridgeBio Pharma	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$100.00 ➝ $111.00
8/11/2026	BBIO BridgeBio Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
8/11/2026	GMAB Genmab A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/11/2026	BBIO BridgeBio Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$110.00
8/11/2026	BBIO BridgeBio Pharma	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$101.00 ➝ $104.00
8/11/2026	BBIO BridgeBio Pharma	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$98.00 ➝ $97.00
8/11/2026	BBIO BridgeBio Pharma	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$95.00 ➝ $110.00
8/11/2026	BBIO BridgeBio Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$98.00 ➝ $102.00

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCM Abcam	$379.70M	14.49	$0.60 per share	40.17	$3.92 per share	6.12
BBIO BridgeBio Pharma	$502.08M	31.11	N/A	N/A	($10.77) per share	-7.42
GMAB Genmab A/S	$3.72B	5.50	$1.66 per share	19.84	$9.10 per share	3.61
UTHR United Therapeutics	$3.18B	6.85	$33.56 per share	15.15	$164.81 per share	3.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCM Abcam	-$10.51M	N/A	N/A	42.09	2.19	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	-$724.93M	-$3.57	N/A	N/A	N/A	-97.03%	N/A	-61.19%	10/28/2026 (Estimated)
GMAB Genmab A/S	$963M	$1.27	25.86	20.27	1.90	19.08%	14.89%	7.73%	11/5/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	18.19	17.14	1.69	41.56%	20.18%	17.98%	11/4/2026 (Estimated)

Latest ABCM, UTHR, GMAB, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	BBIO BridgeBio Pharma	-$0.5756	-$0.78	-$0.2044	-$0.78	$220.91 million	$243.68 million
8/6/2026	Q2 2026	GMAB Genmab A/S	$0.37	$0.54	+$0.17	$0.4910	$1.12 billion	$1.16 billion
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCM Abcam	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCM Abcam	N/A	1.35	1.00
BBIO BridgeBio Pharma	N/A	1.23	1.17
GMAB Genmab A/S	0.81	2.46	2.44
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCM Abcam	90.45%
BBIO BridgeBio Pharma	99.85%
GMAB Genmab A/S	7.07%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ABCM Abcam	6.73%
BBIO BridgeBio Pharma	14.23%
GMAB Genmab A/S	1.54%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCM Abcam	1,760	229.27 million	213.84 million	No Data
BBIO BridgeBio Pharma	400	195.49 million	167.67 million	Optionable
GMAB Genmab A/S	3,029	623.53 million	613.93 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

ABCM, UTHR, GMAB, and BBIO Headlines

Recent News About These Companies

Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

August 17 at 5:06 PM | marketbeat.com

United Therapeutics Completes Enrollment in Phase 3 PPF Trial of Tyvaso

August 17 at 9:08 AM | finance.yahoo.com

United Therapeutics (UTHR) Gets a Buy from Wells Fargo

August 17 at 9:08 AM | theglobeandmail.com

13,981 Shares in United Therapeutics Corporation $UTHR Acquired by Persistent Asset Partners Ltd

August 17 at 6:31 AM | marketbeat.com

Chase Investment Counsel Corp Buys New Position in United Therapeutics Corporation $UTHR

August 17 at 4:16 AM | marketbeat.com

180 GPS Investments IC Ltd Buys New Shares in United Therapeutics Corporation $UTHR

August 17 at 3:04 AM | marketbeat.com

Equities Analysts Offer Predictions for UTHR Q3 Earnings

August 17 at 1:12 AM | americanbankingnews.com

HC Wainwright Issues Positive Forecast for UTHR Earnings

August 17 at 1:11 AM | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Sells $4,892,785.00 in Stock

August 16 at 4:09 AM | americanbankingnews.com

Q4 EPS Forecast for United Therapeutics Lowered by Analyst

August 16 at 1:42 AM | americanbankingnews.com

HC Wainwright Issues Pessimistic Outlook for UTHR Earnings

August 14 at 8:41 AM | marketbeat.com

United Therapeutics’s Q2 earnings call: Our top 5 analyst questions

August 12, 2026 | msn.com

United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript

August 12, 2026 | fool.com

Liquidia, An IBD 50 Stock, Tops Sales Views Amid United Therapeutics Rivalry

August 12, 2026 | investors.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

August 11, 2026 | insidertrades.com

United Therapeutics (NASDAQ:UTHR) EVP Sells $4,291,515.00 in Stock

August 9, 2026 | americanbankingnews.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,928,030.00 in Stock

August 9, 2026 | americanbankingnews.com

Royal Bank Of Canada Cuts United Therapeutics (NASDAQ:UTHR) Price Target to $677.00

August 9, 2026 | americanbankingnews.com

Assenagon Asset Management S.A. Purchases 37,355 Shares of United Therapeutics Corporation $UTHR

August 9, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) Sees Strong Trading Volume - Should You Buy?

August 7, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares

August 7, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCM, UTHR, GMAB, and BBIO Company Descriptions

Abcam NASDAQ:ABCM

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.

BridgeBio Pharma NASDAQ:BBIO

$79.89 +0.03 (+0.04%)

As of 04:00 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Genmab A/S NASDAQ:GMAB

$32.84 +0.90 (+2.82%)

As of 04:00 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

United Therapeutics NASDAQ:UTHR

$508.48 +8.75 (+1.75%)

As of 04:00 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABCM, UTHR, GMAB, and BBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABCM, UTHR, GMAB, and BBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABCM, UTHR, GMAB, and BBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCM, UTHR, GMAB, and BBIO Company Descriptions

Abcam NASDAQ:ABCM

BridgeBio Pharma NASDAQ:BBIO

Genmab A/S NASDAQ:GMAB

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABCM, UTHR, GMAB, and BBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABCM, UTHR, GMAB, and BBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABCM, UTHR, GMAB, and BBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCM, UTHR, GMAB, and BBIO Company Descriptions

Abcam NASDAQ:ABCM

BridgeBio Pharma NASDAQ:BBIO

Genmab A/S NASDAQ:GMAB

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools